The nuclear factor-kappa B activation in mucosa-associated lymphoid tissue (MALT) lymphoma pathogenesis provided the rationale for the evaluation of bortezomib in this malignancy.
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG) / Conconi, A., Martinelli, G., Lopez Guillermo, A., Zinzani, P.L., Ferreri, A.J.M., Rigacci, L., Devizzi, L., Vitolo, U., Luminari, S., Cavalli, F., Zucca, E.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - STAMPA. - 22:3(2011), pp. 689-695. [10.1093/annonc/mdq416]
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)
LUMINARI, Stefano;
2011
Abstract
The nuclear factor-kappa B activation in mucosa-associated lymphoid tissue (MALT) lymphoma pathogenesis provided the rationale for the evaluation of bortezomib in this malignancy.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
